Search research articles
Contact Us
Filters
Showing results (231-240 of 397) with videos related to
Page
of 40
Sort By:
Proceedings of the National Academy of Sciences of the United States of America
|
June 6, 2012
Late Middle Eocene primate from Myanmar and the initial anthropoid colonization of Africa
Yaowalak Chaimanee, Olivier Chavasseau, K Christopher Beard, et al.
British Journal of Cancer
|
February 21, 2018
Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials
Shiraj Sen, Kenneth Hess, David S Hong, et al.
Oncotarget
|
September 28, 2014
Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors
Burhan Hassan, Argun Akcakanat, Takafumi Sangai, et al.
Oncotarget
|
June 11, 2014
Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway
Jennifer J Wheler, Stacy L Moulder, Aung Naing, et al.
Cancer Immunology Research
|
September 5, 2014
Combining radiation and immunotherapy: a new systemic therapy for solid tumors?
Chad Tang, Xiaohong Wang, Hendrick Soh, et al.
Oncotarget
|
March 3, 2016
Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus
Xiaochun Liu, Susan Kambrick, Siqing Fu, et al.
Molecular Cancer Therapeutics
|
January 11, 2011
PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors
Filip Janku, Apostolia M Tsimberidou, Ignacio Garrido-Laguna, et al.
Oncotarget
|
April 22, 2017
Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer
Zhijie Wang, Sarina Piha-Paul, Filip Janku, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 6, 2016
Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer
David Hong, Jeffrey Infante, Filip Janku, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 25, 2012
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations
Filip Janku, Jennifer J Wheler, Shannon N Westin, et al.
Page
of 40
Search research articles
Search
Showing results (231-240 of 397) with videos related to
Sort By:
Page
of 40
Proceedings of the National Academy of Sciences of the United States of America
|
June 6, 2012
Late Middle Eocene primate from Myanmar and the initial anthropoid colonization of Africa
Yaowalak Chaimanee, Olivier Chavasseau, K Christopher Beard, et al.
British Journal of Cancer
|
February 21, 2018
Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials
Shiraj Sen, Kenneth Hess, David S Hong, et al.
Oncotarget
|
September 28, 2014
Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors
Burhan Hassan, Argun Akcakanat, Takafumi Sangai, et al.
Oncotarget
|
June 11, 2014
Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway
Jennifer J Wheler, Stacy L Moulder, Aung Naing, et al.
Cancer Immunology Research
|
September 5, 2014
Combining radiation and immunotherapy: a new systemic therapy for solid tumors?
Chad Tang, Xiaohong Wang, Hendrick Soh, et al.
Oncotarget
|
March 3, 2016
Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus
Xiaochun Liu, Susan Kambrick, Siqing Fu, et al.
Molecular Cancer Therapeutics
|
January 11, 2011
PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors
Filip Janku, Apostolia M Tsimberidou, Ignacio Garrido-Laguna, et al.
Oncotarget
|
April 22, 2017
Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer
Zhijie Wang, Sarina Piha-Paul, Filip Janku, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 6, 2016
Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer
David Hong, Jeffrey Infante, Filip Janku, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 25, 2012
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations
Filip Janku, Jennifer J Wheler, Shannon N Westin, et al.
Page
of 40